Wound botulism from heroin skin popping

Current Neurology and Neuroscience Reports

Volumn 8, Issue 6, 2008, Pages 462-468

  Davis, Larry E ^a   King, Molly K ^a  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; DIAGNOSTIC AGENT; DIAMORPHINE;

ACTION POTENTIAL; ANIMAL; ARTICLE; BLOOD; BOTULISM; CLOSTRIDIUM BOTULINUM; ELECTRODIAGNOSIS; FEMALE; HUMAN; MALE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; WOUND INFECTION;

ACTION POTENTIALS; ANIMALS; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; ELECTRODIAGNOSIS; FEMALE; HEROIN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; WOUND INFECTION;

EID: 58149193723     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-008-0074-2     Document Type: Article

References (47)

1. Centers for Disease Control and Prevention: Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Atlanta, GA: Centers for Disease Control and Prevention; 1998.
2. Weber JT, Goodpasture HC, Alexander H, et al.: Wound botulism in a patient with a tooth abscess: case report and review. Clin Infect Dis 1993, 16:635-639. (Pubitemid 23136561)
3. Merson MH, Dowell VR: Epidemiologic, clinical and laboratory aspects of wound botulism. N Engl J Med 1973, 289:1005-1010.
4. Werner SB, Passaro D, McGee J, et al.: Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis 2000, 31:1018-1024. (Pubitemid 32299363)
5. MacDonald KL, Rutherford GW, Friedman S, et al.: Botulism and botulism-like illnesses in chronic drug users. Ann Intern Med 1985, 102:616-618. (Pubitemid 15120480)
6. Passario DJ, Werner SB, McGee J, et al.: Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998, 279:859-863. (Pubitemid 28185551)
7. Centers for Disease Control and Prevention: Summary of notifiable diseases-United States, 2005. MMWR Morb Mortal Wkly Rep 2007, 54:2-92.
8. Brett MM, Hallas G, Mpamugo O: Wound botulism in the UK and Ireland. J Med Microbiol 2004, 53:555-561. (Pubitemid 38803053)
9. Galldiks N, Nolden-Hoverath S, Kosinski CM, et al.: Rapid geographical clustering of wound botulism in Germany after subcutaneous and intramuscular injection of heroin. Neurocrit Care 2007, 6:630-634.
10. Kudrow DB, Henry DA, Haake DA, et al.: Botulism associated with Clostridium botulinum sinusitis after intranasal cocaine abuse. Ann Intern Med 1988, 109:984-985. (Pubitemid 19046068)
11. Sobel J: Botulism. Clin Infect Dis 2005, 41:1167-1173. This is a review article from the CDC on the various types of botulism and the differential diagnosis. (Pubitemid 41429481)
12. Bleck TP: Clostridium botulinum (botulism). In Principles and Practice of Infectious Diseases, edn 5. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone; 2000:2543-2548.
13. Microbiological investigation into wound botulism. Commun Dis Rep CDR Wkly 2000, 10:185, 188.
14. Simpson LL: Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004, 44:167-193. (Pubitemid 38263838)
15. Hatheway CL, Ferreira JL: Detection and identification of Clostridium botulinum neurotoxins. Adv Exp Med Biol 1996, 391:481-498. (Pubitemid 26176348)
16. Sugiyama H: Clostridium botulinum neurotoxin. Microbiol Rev 1980, 44:419-448. (Pubitemid 11229395)
17. Horowitz BZ: Botulinum toxin. Crit Care Clin 2005, 21:825-839. (Pubitemid 41306220)
18. Pestronk A, Drachman DB: Motor nerve outgrowth: reduced capacity for sprouting in the terminals of longer axons. Brain Res 1988, 463:218-222.
19. US Drug Enforcement Administration: Heroin: description/overview. Available at http://www.usdoj.gov/dea/concern/heroin.html. Accessed September 25, 2008.
20. National Institute on Drug Abuse: Heroin Abuse and Addiction. Available at http://www.drugabuse. gov/ResearchReports/Heroin/Heroin.html. Accessed September 25, 2008.
21. Maselli RA, Ellis W, Mandler RN, et al.: Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve 1997, 20:1284-1295. (Pubitemid 27415517)
22. US Public Health Service: National Household Survey on Drug Abuse: Population Estimates 1994. Rockville, MD: US Department of Health and Human Services; 1995. [DHHS publication SMA 95-3093.]
23. Penas SC, Faria OM, Serrao R, et al.: Ophthalmic manifestations in 18 patients with botulism diagnosed in Porto, Portugal between 1998 and 2003. J Neuroophthalmol 2005, 25:262-267. (Pubitemid 44481147)
24. Cooper JG, Spilke CE, Benton M, Jamieson S: Clostridium botulinum: an increasing complication of heroin misuse. Eur J Emerg Med 2005, 12:251-252.
25. Mitchell PA, Pons PT: Wound botulism associated with black tar heroin and lower extremity cellulitis. J Emerg Med 2001, 20:371-375. (Pubitemid 32448011)
26. Centers for Disease Control and Prevention: Wound botulism-California, 1995. MMWR Morb Mortal Wkly Rep 2005, 44:889-892.
27. American Association of Neuromuscular and Electrodiagnostic Medicine: Practice Parameter for Repetitive Nerve Stimulation and Single Fiber EMG Evaluation of Adults With Suspected Myasthenia Gravis or Lambert-Eaton Myasthenic Syndrome: Summary Statement. Available at http://www.aanem.org/ education/practiceguidelines/mg.cfm. Accessed September 25, 2008.
28. De Jesus PV Jr, Slater R, Spitz LK, Penn AS: Neuromuscular physiology of wound botulism. Arch Neurol 1973, 29:415-431.
29. Shapiro BE, Soto O, Shafqat S, Bluenfeld H: Adult botulism. Muscle Nerve 1997, 20:100-102. (Pubitemid 27009476)
30. Ryan DW, Cherington M: Human type A botulism. JAMA 1971, 216:513-514.
31. Edel TA, Sullivan CP, Osborn KM, et al.: Wound botulism associated with a positive Tensilon test. West J Med 1983, 139:218-219. (Pubitemid 13041990)
32. Lo YL: Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve 2007, 36:615-627. (Pubitemid 47623849)
33. Robinson RF, Nahata MC: Management of botulism. Ann Pharmacother 2003, 37:127-131. (Pubitemid 36068612)
34. Lindstrom M, Korkeala H: Laboratory diagnosis of botulism. Clin Microbiol Rev 2006, 19:298-314.
35. Mulleague L, Bonner SM, Samuel A, et al.: Wound botulism in drug addicts in the United Kingdom. Anesthesia 2001, 56:120-123. (Pubitemid 32185881)
36. Davis LE: Botulism. Curr Treat Option Neurol 2003, 5:23-31.
37. Sandrock DF, Murin S: Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest 2001, 120:562-566. (Pubitemid 32881276)
38. Kramer AH, Bleck TP: Neurocritical care of patients with central nervous system infections. Curr Infect Dis Rep 2007, 9:308-314. (Pubitemid 47162240)
39. Tacket CO, Shandera WX, Mann JM, et al.: Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984, 76:794-798. (Pubitemid 14142677)
40. Hatheway CL, Snyder JD, Seals JE, et al.: Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984, 150:407-412. (Pubitemid 14037027)
41. Arnon SS, Schechter R, Inglesby TV, et al.: Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070. (Pubitemid 32176420)
42. Black RE, Gunn RA: Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980, 69:567-570. (Pubitemid 10018712)
43. Santos JI, Swensen P, Glasgow LA: Potentiation of Clostridium botulinum toxin by aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981, 68:50-54. (Pubitemid 11061363)
44. Mechem CC, Walter FG: Wound botulism. Vet Hum Toxicol 1994, 36:233-237. (Pubitemid 24177992)
45. Woodruff BA, Griffin PM, McCroskey LM, et al.: Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis 1992, 166:1281-1286.
46. Mann JM, Martin S, Hoffman R, Marrazzo S: Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health 1981, 71:266-269. (Pubitemid 11146410)
47. Keller JE: Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 2006, 139:629-637.